FDA fast tracks Erasca's pan-RAS molecular glue after early pancreatic cancer responses

The FDA granted Fast Track Designation to Erasca's ERAS-0015, an oral pan-RAS molecular glue for metastatic pancreatic adenocarcinoma, enabling expedited regulatory interactions and potential accelerated approval. The designation follows promising early phase data showing significant response rates with manageable toxicity.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.